DOCSLIB.ORG

Drugs with Special Ordering Procedures (SAP Chart)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drugs with Special Ordering Procedures (SAP Chart) Drugs With Special Ordering Procedures (SAP Chart) Drug Supplier BC Cancer Requirements Ordering Procedures Abemaciclib Eli Lilly Canada Not funded by BC Cancer Now marketed. (Verzenio®) Phone: 1-888-545-5972 Contact Patient Support program effective mid-July 2019 Abiraterone Janssen Ortho CAP approval Now marketed tel: 416-382-5078 or 416-805- See Patient Assistance Programs 4648 AGS-16C3F – SAP Astellas Pharma USA CAP approval (no cost) Health Canada Special Access Request Form A Phone 1-224-205-8279 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- drogues/index-eng.php Alemtuzumab Genzyme • Contact Clnigen Group to open an account – (MABCAMPATH®) Phone: 905-267-3184 company will send a Cliniport registration form • Complete Cliniport Registration form with an email Distributed through the address for authorizing physician(s) MabCampath Distribution and pharmacist(s) placing the order via Cliniport Program and fax back to +44 1283 494341 which is managed by the • Once registered, company will send guidance on Clinigen Group using the Cliniport portal for ordering, tracking www.clinigengroup.com orders, reassigning vials, and closing out patients records Phone : +44 1283 494340 • Reports detailing all shipments and current status of Fax: +44 1283 494341 Campath can be downloaded through the Cliniport Email: portal customer.services@clinigengr oup.com Alpelisib Novartis Canada Not funded by BC Cancer Now marketed. (Piqray®) Contact Patient Support Program: Piqray PSP 1-877-516-5353 Atezolizumab Hoffmann-La Roche Not currently funded by BC Cancer. Now marketed. (TECENTRIQ®) See Patient Assistance Programs Amivantamab-vmjw Janssen (no cost) Health Canada Special Access Request Form A SAP Tel: 1-800-567-3331 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- [email protected] drogues/index-eng.php 8 Sep 2021 1/18 Drugs With Special Ordering Procedures (SAP Chart) Drug Supplier BC Cancer Requirements Ordering Procedures Avelumab – SAP EMD Serono CAP approval Now marketed (Bavencio®) A Business of Merck KGaA, Darmstadt, Germany EMD Inc., Canada | 200-2695 North Sheridan Way | Mississauga, Ontario L5K 2N6 | Canada Phone: +1 905 919 0200 ext. 5534 | Mobile: +1 416-729- 3254 | Fax: +1 905 919 0299 www.emdserono.ca Azacitidine - Celgene: CAP approval Now marketed (VIDAZA®) 1-888-712-2353 ext 4807 Aztreonam - SAP Bristol-Myers For inpatients only: (AZACTAM®) 1-514-333-2037 Health Canada Special Access Request Form A http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- drogues/index-eng.php Bazedoxifene – SAP Martina Vlahakis CAP approval (no cost) Health Canada Special Access Request Form A (CONBRIZA) Pfizer Canada http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- Tel: 514-695-0500 or 877- drogues/index-eng.php 633-2001 Belantamab mafodotin GSK (no cost) Health Canada Special Access Request Form A – SAP (also known as Tel: +44 20 8047 4856 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- GSK2857916) drogues/index-eng.php Belinostat – SAP Servier Canada CAP approval (no cost) Health Canada Special Access Request Form A (Beleodaq®) Tel: 450-978-0409 #4381 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- drogues/index-eng.php Bexarotene - SAP Valeant Pharmaceuticals CAP approval (cost) Health Canada Special Access Request Form A (TARGRETIN®) Phone: 1-800-361-4261 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- Email: drogues/index-eng.php [email protected] m 8 Sep 2021 2/18 Drugs With Special Ordering Procedures (SAP Chart) Drug Supplier BC Cancer Requirements Ordering Procedures Brigatinib Takeda Canada Not funded by BC Cancer Now marketed (ALUNBRIG®) 1-844-884-4968 Contact the Patient Assistance Program Tel: 844-884-4968 Buprenorphine – SAP Indivior (no cost) Pre-approval from company required. (Sublocade®) tel: 514-331-1114 Shipped to BC Cancer but transfer to outside pharmacy to dispense Health Canada Special Access Request Form A http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- drogues/index-eng.php Cabozantinib Ipsen Canada Not funded by BC Cancer Now marketed. Contact Ipsen Cares Patient Support (Cobometyx®) tel: 1-855-215-2218 Porgram (1-855-215-2288) for drug access. Canakinumab Novartis Not funded by BC Cancer Contact the Patient Assistance Program (IDARIA®) EXPOSE – 1-844-279-7673 Capmatinib - SAP Novartis Canada CAP approval (no Cost) Health Canada Special Access Request Form A (Tabrecta®) Fax 1-416-262-4992 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- Email drogues/index-eng.php [email protected] Pre-approval from drug company. om Carbidopa – SAP Merke-Frosst N/A Now marketed tel: 1-800-361-7031 x3212 Carfilzomib Amgen Not currently funded by BC Cancer Now marketed - (Kyprolis®) Contact the Victory Program (1-888-706-4717) for drug access and private infusion clinic Carmustine Heritage Pharmaceuticals Inc Now marketed 732-429-1000 local 132 8 Sep 2021 3/18 Drugs With Special Ordering Procedures (SAP Chart) Drug Supplier BC Cancer Requirements Ordering Procedures Carmustine Implant Eisai Limited CAP approval (cost) Health Canada Special Access Request Form A (GLIADEL® Wafers) - Company contact http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- SAP Alex Flint Medical Director drogues/index-eng.php Phone: 647-299-2983 or 905-361-7137 Email: [email protected] Distributor – Idis/Clinigen [email protected] Cediranib-SAP Astra Zeneca CAP approval (no cost) Pre-approval from company required. Tel: 1-800-565-5877 Email: Health Canada Special Access Request Form A sapcanadaastrazeneca@astr http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- azeneca.com drogues/index-eng.php Cemiplimab Sanofi Not funded at BC Cancer Now marketed REACH Patient Support Program (Libtayo®) Tel: 1-855-572-6634 Fax: 1-844-342-4534 Chlormethine Recordarti (cost) Health Canada Special Access Request Form A Hydrochorine – SAP Tel: 647-255-8830 Alternative to mechlorethamine http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- (Legara®) drogues/index-eng.php Chloroprocaine - SAP Fresenius Kabi N/A Health Canada Special Access Request Form A (NESACAINE®) Tel: 905-238-1234 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- email: abascom@fresenius- drogues/index-eng.php kabi.ca Cisplatin, lyophilized Bristol-Myers Squibb Not currently marketed in Canada. powder, – SAP tel: 514-333-2287 Not currently available through SAP. (PLATINOL®) Clofarabine Sanofi Genzyme Canada Health Canada Special Access Request Form A SAP (Evoltra®) Tel: 1-800-265-7927 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- SAP supply from UK drogues/index-eng.php during back order Drug provided free of charge by company. period in Canada 8 Sep 2021 4/18 Drugs With Special Ordering Procedures (SAP Chart) Drug Supplier BC Cancer Requirements Ordering Procedures Cytarabine Hospira No longer on back order. tel: 1-866-488-6088 Cytarabine liposome sigma-tau Rare dedication CAP approval (cost) Health Canada Special Access Request Form A injection - SAP Support Centre http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- (DEPOCYT®) US Discontinued by manufacturer (May drogues/index-eng.php tel: 1-888-276-2217 2018) fax: 1-866-489-1898 Daratumumab Janssen Not currently funced by BC Cancer Now Marketed (DARAZALEX®) (cost) See Patient Assistance Programs Daunorubicin – liposomal - SAP Please see DaunoXome® - SAP DaunoXome® - SAP GALEN PHARMA (UK) CAP approval Health Canada Special Access Request Form A (liposomal Phone:02838334974 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- daunorubicin) Email: [email protected] drogues/index-eng.php Decitabine – SAP Eisai CAP approval Health Canada Special Access Request Form A (DACOGEN®) Arlene Nugent http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- phone: 647-302-2947 drogues/index-eng.php email: [email protected] Denileukin Diftiox - Ligand Pharmaceuticals CAP approval Health Canada Special Access Request Form A SAP 1-508-435-8484 x 353 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- (ONTAK®) drogues/index-eng.php Dexrazoxane Pfizer CAP approval No longer on back order (ZINECARD®) tel: 1-800-387-4974 8 Sep 2021 5/18 Drugs With Special Ordering Procedures (SAP Chart) Drug Supplier BC Cancer Requirements Ordering Procedures Diazoxide – SAP Teva Pharmaceuticals CAP approval Health Canada Special Access Request Form A (Proglycem®) Sellerville, PA, USA 18960 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- Phone : 305-575-6284 drogues/index-eng.php Dostarlimab – SAP GSK (no cost) Health Canada Special Access Request Form A (also known as TSR- tel: +44 20 8047 4856 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- 042) drogues/index-eng.php Doxorubicin – non- pegylated liposomal Please see MYOCET® Eltrombopag Glaxo See Patient Assistance Programs Not funded by BC Cancer. Encorafenib – SAP Pfizer Canada CAP approval (no cost) Health Canada Special Access Request Form A Tel: 514-426-7487 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- drogues/index-eng.php Company pre-approval. Enfortumab Vedotin – Seagen Canada (no cost) Health Canada Special Access Request Form A SAP Tel: 1-833-944-6546 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- drogues/index-eng.php Erwinase CGF Pharmatech (cost) Health Canada Special Access Request Form A l-asparaginase - SAP 1-866-343-0344 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- (ERWINASE®) drogues/index-eng.php Etomidate – SAP Hospira Health Canada Special Access Request Form B (for (AMIDATE®) Tel: 514-905-2619 future use) http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- drogues/index-eng.php Etoposide phosphate - Xedition CAP approval (cost) Health Canada Special Access Request Form A SAP Tel: 905-286-9111 http://www.hc-sc.gc.ca/dhp-mps/acces/drugs- (ETOPOPHOS®) drogues/index-eng.php 8 Sep 2021 6/18 Drugs With Special
Load more

Recommended publications
  • Ripretinib Demonstrated Activity Across All KIT/PDGFRA Mutations In
    Ripretinib demonstrated activity across all KIT/PDGFRA mutations in patients with fourth-line advanced gastrointestinal stromal tumor: Analysis from the phase 3 INVICTUS study Patrick Schöffski1, Sebastian Bauer2, Michael Heinrich3, Suzanne George4, John Zalcberg5, Hans Gelderblom6, Cesar Serrano Garcia7, Robin L Jones8, Steven Attia9, Gina D’Amato10, Ping Chi11, Peter Reichardt12, Julie Meade13, Kelvin Shi13, Ying Su13, Rodrigo Ruiz-Soto13, Margaret von Mehren14, Jean-Yves Blay15 1University Hospitals Leuven, Leuven, Belgium; 2West German Cancer Center, Essen, Germany; 3OHSU Knight Cancer Institute, Portland, OR, USA; 4Dana-Farber Cancer Institute, Boston, MA, USA; 5Monash University, Melbourne, VIC, Australia; 6Leiden University Medical Center, Leiden, Netherlands; 7Vall d’Hebron Institute of Oncology, Barcelona, Spain; 8Royal Marsden and Institute of Cancer Research, London, UK; 9Mayo Clinic, Jacksonville, FL, USA; 10Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA; 11Memorial Sloan Kettering Cancer Center, New York, NY, USA; 12Sarcoma Center, Helios Klinikum Berlin-Buch, Berlin, Germany; 13Deciphera Pharmaceuticals, LLC, Waltham, MA, USA; 14Fox Chase Cancer Center, Philadelphia, PA, USA; 15Centre Leon Berard, Lyon, France KIT mutation analysis by combined tumor and liquid biopsy INTRODUCTION RESULTS Figure 7. Hazard ratio of PFS with different mutation groups by combined • Patients were grouped into 4 subsets: any KIT exon 9, any KIT exon 11, any KIT exon 13, and any KIT exon 17 tumor and liquid biopsy • Patients
    [Show full text]
  • PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
    International Journal of Molecular Sciences Review PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects Rosalin Mishra , Hima Patel, Samar Alanazi , Mary Kate Kilroy and Joan T. Garrett * Department of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267-0514, USA; [email protected] (R.M.); [email protected] (H.P.); [email protected] (S.A.); [email protected] (M.K.K.) * Correspondence: [email protected]; Tel.: +1-513-558-0741; Fax: +1-513-558-4372 Abstract: The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and completed clinical trials involving PI3K inhibitors (pan, isoform-specific and dual PI3K/mTOR) with the goal to find efficient PI3K inhibitors that could overcome resistance to current therapies. This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in different cancer types. There is a discussion of the drug-related toxicities, challenges associated with these PI3K inhibitors and the adverse events leading to treatment failure. In addition, novel PI3K drugs that have potential to be translated in the clinic are highlighted. Keywords: cancer; PIK3CA; resistance; PI3K inhibitors Citation: Mishra, R.; Patel, H.; Alanazi, S.; Kilroy, M.K.; Garrett, J.T.
    [Show full text]
  • Nimotuzumab, an Antitumor Antibody That Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding While Permitting the Active Receptor Conformation
    Published OnlineFirst July 7, 2009; DOI: 10.1158/0008-5472.CAN-08-4518 Experimental Therapeutics, Molecular Targets, and Chemical Biology Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation Ariel Talavera,1,2 Rosmarie Friemann,2,3 Silvia Go´mez-Puerta,1 Carlos Martinez-Fleites,4 Greta Garrido,1 Ailem Rabasa,1 Alejandro Lo´pez-Requena,1 Amaury Pupo,1 Rune F. Johansen,3 Oliberto Sa´nchez,5 Ute Krengel,2 and Ernesto Moreno1 1Center of Molecular Immunology, Havana, Cuba; 2Department of Chemistry, University of Oslo, Oslo, Norway; and 3Center for Molecular and Behavioral Neuroscience, Institute of Medical Microbiology, University of Oslo, Rikshospitalet HF, Oslo, Norway; 4Department of Chemistry, University of York, Heslington, York, United Kingdom; and 5Center for Genetic Engineering and Biotechnology, Havana, Cuba Abstract region of the EGFR (eEGFR), leaving the dimerization ‘‘arm’’ in Overexpression of the epidermal growth factor (EGF) receptor domain II ready for binding a second monomer (4, 5). It has been (EGFR) in cancer cells correlates with tumor malignancy and shown that the eEGFR adopts a ‘‘tethered’’ or inactive conformation poor prognosis for cancer patients. For this reason, the EGFR in the absence of EGF (6). In this characteristic conformation, has become one of the main targets of anticancer therapies. the dimerization arm is hidden by interactions with domain IV, Structural data obtained in the last few years have revealed whereas domains I and III remain separated. Thus, to adopt the the molecular mechanism for ligand-induced EGFR dimeriza- ‘‘extended’’ or active conformation observed in the crystal structure tion and subsequent signal transduction, and also how this of the complex with EGF (4), the receptor must undergo a major signal is blocked by either monoclonal antibodies or small conformational change that brings together domains I and III (6).
    [Show full text]
  • Targeted and Novel Therapy in Advanced Gastric Cancer Julie H
    Selim et al. Exp Hematol Oncol (2019) 8:25 https://doi.org/10.1186/s40164-019-0149-6 Experimental Hematology & Oncology REVIEW Open Access Targeted and novel therapy in advanced gastric cancer Julie H. Selim1 , Shagufta Shaheen2 , Wei‑Chun Sheu3 and Chung‑Tsen Hsueh4* Abstract The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of angiogenesis, human epidermal growth factor receptor 2 (HER2), mesenchymal–epithelial transition, epidermal growth factor receptor, mammalian target of rapamycin, claudin‑18.2, programmed death‑1 and DNA. Addition of trastuzumab to platinum‑ based chemotherapy has become standard of care as front‑line therapy in advanced GC overexpressing HER2. In the second‑line setting, ramucirumab with paclitaxel signifcantly improves overall survival compared to paclitaxel alone. For patients with refractory disease, apatinib, nivolumab, ramucirumab and TAS‑102 have demonstrated single‑agent activity with improved overall survival compared to placebo alone. Pembrolizumab has demonstrated more than 50% response rate in microsatellite instability‑high tumors, 15% response rate in tumors expressing programmed death ligand 1, and non‑inferior outcome in frst‑line treatment compared to chemotherapy. This review summarizes the current state and progress of research on targeted therapy for advanced GC. Keywords: Gastric cancer, Targeted therapy, Human epidermal growth factor receptor 2, Programmed death‑1, Vascular endothelial growth factor receptor 2 Background GC mortality which is consistent with overall decrease in Gastric cancer (GC), including adenocarcinoma of the GC-related deaths [4]. gastroesophageal junction (GEJ) and stomach, is the ffth Tere have been several eforts to perform large-scale most common cancer and the third leading cause of can- molecular profling and classifcation of GC.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • (CHMP) Agenda for the Meeting on 22-25 February 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
    22 February 2021 EMA/CHMP/107904/2021 Human Medicines Division Committee for medicinal products for human use (CHMP) Agenda for the meeting on 22-25 February 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes 22 February 2021, 09:00 – 19:30, room 1C 23 February 2021, 08:30 – 19:30, room 1C 24 February 2021, 08:30 – 19:30, room 1C 25 February 2021, 08:30 – 19:30, room 1C Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021.
    [Show full text]
  • Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers
    Published OnlineFirst June 12, 2020; DOI: 10.1158/2159-8290.CD-20-0163 RESEARCH ARTICLE Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers Timothy A. Yap1,2, Rebecca Kristeleit3, Vasiliki Michalarea1, Stephen J. Pettitt4,5, Joline S.J. Lim1, Suzanne Carreira2, Desamparados Roda1,2, Rowan Miller3, Ruth Riisnaes2, Susana Miranda2, Ines Figueiredo2, Daniel Nava Rodrigues2, Sarah Ward1,2, Ruth Matthews1,2, Mona Parmar1,2, Alison Turner1,2, Nina Tunariu1, Neha Chopra1,4, Heidrun Gevensleben2, Nicholas C. Turner1,4, Ruth Ruddle2, Florence I. Raynaud2, Shaun Decordova2, Karen E. Swales2, Laura Finneran2, Emma Hall2, Paul Rugman6, Justin P.O. Lindemann6, Andrew Foxley6, Christopher J. Lord4,5, Udai Banerji1,2, Ruth Plummer7, Bristi Basu8, Juanita S. Lopez1,2, Yvette Drew7, and Johann S. de Bono1,2 Downloaded from cancerdiscovery.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Published OnlineFirst June 12, 2020; DOI: 10.1158/2159-8290.CD-20-0163 ABSTRACT Preclinical studies have demonstrated synergy between PARP and PI3K/AKT path- way inhibitors in BRCA1 and BRCA2 (BRCA1/2)–deficient andBRCA1/2 -proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective intrapatient dose- escalation design to assess two schedules of capivasertib (AKT inhibitor) with olaparib (PARP inhibi- tor) in 64 patients with advanced solid tumors. Dose expansions enrolled germline BRCA1/2-mutant tumors, or BRCA1/2 wild-type cancers harboring somatic DNA damage response (DDR) or PI3K–AKT pathway alterations. The combination was well tolerated. Recommended phase II doses for the two schedules were: olaparib 300 mg twice a day with either capivasertib 400 mg twice a day 4 days on, 3 days off, or capivasertib 640 mg twice a day 2 days on, 5 days off.
    [Show full text]
  • Clinical Policy: Sorafenib (Nexavar)
    Clinical Policy: Sorafenib (Nexavar) Reference Number: CP.PHAR.69 Effective Date: 07.01.11 Last Review Date: 05.21 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Sorafenib (Nexavar®) is a kinase inhibitor. FDA Approved Indication(s) Nexavar (sorafenib) is indicated for the treatment of: Unresectable hepatocellular carcinoma (HCC); Advanced renal cell carcinoma (RCC); Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Nexavar is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Hepatocellular Carcinoma (must meet all): 1. Diagnosis of HCC; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Confirmation of Child-Pugh class A or B7 status; 5. Request meets one of the following (a or b):* a. Dose does not exceed 800 mg per day; b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence). *Prescribed regimen must be FDA-approved or recommended by NCCN Approval duration: Medicaid/HIM – 6 months Commercial – Length of Benefit B. Renal Cell Carcinoma (must meet all): 1. Diagnosis of advanced RCC; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Request meets one of the following (a or b):* Page 1 of 8 CLINICAL POLICY Sorafenib a.
    [Show full text]
  • Treatment and Testing Guidelines
    For patients with METex14 and BRAF V600E in mNSCLC, TREATMENT AND TESTING GUIDELINES METex14 BRAF V600E BRAF, v-raf murine sarcoma viral oncogene homolog B1; MET, mesenchymal-epithelial transition; METex14, MET exon 14 skipping; mNSCLC, metastatic non-small cell lung cancer. Indication Indication TABRECTA® (capmatinib) tablets is indicated for the TAFINLAR® (dabrafenib) capsules, in combination with treatment of adult patients with metastatic non-small MEKINIST® (trametinib) tablets, is indicated for the cell lung cancer (NSCLC) whose tumors have a mutation treatment of patients with metastatic non-small cell that leads to mesenchymal-epithelial transition (MET) lung cancer (NSCLC) with BRAF V600E mutation as exon 14 skipping as detected by an FDA-approved test. detected by an FDA-approved test. This indication is approved under accelerated approval Limitation of Use: TAFINLAR is not indicated for the based on overall response rate and duration of treatment of patients with wild-type BRAF NSCLC. response. Continued approval for this indication may be contingent upon verification and description of clinical Important Safety Information benefit in confirmatory trials. New Primary Malignancies. Important Safety Information Cutaneous Malignancies Interstitial Lung Disease (ILD)/Pneumonitis. Across clinical trials of TAFINLAR administered with ILD/pneumonitis, which can be fatal, occurred in MEKINIST (“the combination”), the incidence patients treated with TABRECTA. ILD/pneumonitis of cutaneous squamous cell carcinomas (cuSCCs), occurred in 4.5% of patients treated with TABRECTA including keratoacanthomas, occurred in 2% of in the GEOMETRY mono-1 study, with 1.8% of patients patients. Basal cell carcinoma and new primary experiencing grade 3 ILD/pneumonitis and 1 patient melanoma occurred in 3% and <1% of patients, experiencing death (0.3%).
    [Show full text]
  • Alpelisib Plus Fulvestrant in PIK3CA-Altered
    Clinical Development BYL719 Clinical Trial Protocol CBYL719X2101 A phase IA, multicenter, open-label dose escalation study of oral BYL719, in adult patients with advanced solid malignancies, whose tumors have an alteration of the PIK3CA gene Authors Document type Amended Protocol Version EUDRACT number 2010-018782-32 Version number 09 (Clean) Development phase Ia Document status Final Release date 03-Dec-2015 Property of Novartis Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Novartis Downloaded From: https://jamanetwork.com/ on 09/27/2021 Novartis Confidential Page 2 Amended Protocol Version 09 (Clean) Protocol No. CBYL719X2101 Table of contents Table of contents ................................................................................................................. 2 List of figures ...................................................................................................................... 5 List of tables ........................................................................................................................ 5 List of Post-text supplements (PTS) .................................................................................... 6 List of abbreviations ............................................................................................................ 7 Amendment 9 .................................................................................................................... 11 Oncology clinical study protocol synopsis .......................................................................
    [Show full text]
  • SGO-2020-Annual-Meet
    Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer Abstracts for Oral Presentation Scientific Plenary I: Shaping the Future with Innovative Clinical Trials: A Clearer Vision Ahead in Gynecologic Cancer 1 - Scientific Plenary Sentinel lymph node biopsy versus lymphadenectomy for high-grade endometrial cancer staging (SENTOR trial): A prospective multicenter cohort study M.C. Cusimanoa, D. Vicusb, K. Pulmanc, M.Q. Bernardinid, S. Laframboised, T. Mayd, G. Bouchard-Fortierd, L. Hogend, L.T. Gienb, A.L. Covensb, R. Kupetse, B.A. Clarkea, M. Cesaric, M. Rouzbahmand, J. Mirkovicb, G. Turashvilid, M. Magantid, A. Ziad, G.E.V. Ened and S.E. Fergusond. aUniversity of Toronto, Toronto, ON, Canada, bSunnybrook Odette Cancer Centre, Toronto, ON, Canada, cTrillium Health Partners, Credit Valley Hospital/University of Toronto, Mississauga, ON, Canada, dPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, eSunnybrook Cancer Centre/University of Toronto, Toronto, ON, Canada Objective: It is unclear whether sentinel lymph node biopsy (SLNB) can replace complete lymphadenectomy in women with high-grade endometrial cancer (EC). We performed a prospective multicenter cohort study (the SENTOR trial) to evaluate the performance characteristics of SLNB using indocyanine green (ICG) in stage I high-grade EC (ClinicalTrials.gov ID: NCT01886066). Method: Patients with clinical stage I grade 2 endometrioid or high-grade EC (grade 3 endometrioid, serous, clear cell, carcinosarcoma, undifferentiated, or mixed tumors) undergoing laparoscopic or robotic surgery at 3 cancer centers in Toronto, Canada, were prospectively recruited for SLNB with ICG. After SLNB, high-grade EC patients underwent pelvic and paraaortic lymphadenectomy (PLND/PALND), and grade 2 endometrioid EC patients underwent PLND only.
    [Show full text]
  • Cogent Biosciences Announces Creation of Cogent Research Team
    Cogent Biosciences Announces Creation of Cogent Research Team April 6, 2021 Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million supports company goals into 2024, including three CGT9486 clinical trials on-track to start this year, beginning with ASM in 1H21 BOULDER, Colo. and CAMBRIDGE, Mass., April 6, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the formation of the Cogent Research Team led by newly appointed Chief Scientific Officer, John Robinson, PhD. "Today marks an important step forward for Cogent Biosciences as we announce the formation of the Cogent Research Team with a focus on discovering and developing new small molecule therapies for patients fighting rare, genetically driven diseases," said Andrew Robbins, President and Chief Executive Officer of Cogent Biosciences. "I am thrilled to welcome John onboard as Cogent Biosciences' Chief Scientific Officer. John's expertise and seasoned leadership make him ideally suited to lead this new team of world class scientists. Given the team's impressive experience and accomplishments, we are excited for Cogent Biosciences' future and the opportunity to expand our pipeline and deliver novel precision therapies for patients." With an exceptional track record of innovation, the Cogent Research Team will focus on pioneering best-in-class, small molecule therapeutics to both improve upon existing drugs with clear limitations, as well as create new breakthroughs for diseases where others have been unable to find solutions.
    [Show full text]